Wayne Dimech examines the quality - or lack thereof - of SARS-Cov-2 testing. Wayne Dimech is Executive Manager, Scientific and Business Relations at NRL, Australia (NRL) in Melbourne. He is a recognized expert in infectious disease serology and laboratory quality.
A few months into the Covid19 crisis, we need to stop treating it as a short-term crisis and start preparing it like it's a long-term emergency.
We know how to change QC frequency in a data-driven, evidence-based, patient-risk focused way. But we don't seem to be doing it at all.
Expanding on a previous lesson on Clinical Agreement, Dr. Westgard discusses the Predictive Value of a Laboratory Test
It's October 2020. Time to take a hard look at truth, untruth, and the consequences of pretending there's no difference.
By mid-October 2020, the list of methods for SARS-COV-2 testing (molecular, antigen, rapid, and serology), broke the 870 mark. Rather than ask laboratories to evaluate more than 870 possibilities, we've narrowed the candidates down to a short list.
Continuing in our series of Sigma analysis of the leading diagnostic platforms, we turn our attention to the Abbott Alinity, and assess what goals can be achieved by this chemistry instrument.